Lymphoma & Myeloma 2012

 
 
 

Lymphoma & Myeloma 2012 took place October 25-27 in New York, New York.

 

Treating ALCL associated with breast implants

Mark Fuerst Read Article
Published: 11/16/12

breast_implant_silicone_Credit_FDA_230.jpg
Silicone breast implant
Credit: FDA

Breast-implant-associated anaplastic large-cell lymphoma (ALCL) may represent a new clinical entity with less aggressive, indolent behavior, according to an expert. An FDA analysis of women with ALK-negative ALCL who also had breast implants revealed a small but increased risk of developing the disease in the scar capsule adjacent to the implant, said Thomas Habermann, MD, of the Mayo Clinic in Rochester, Minnesota. He discussed this risk and methods for treating patients . . . [Read Article]

How to treat DLBCL in the over-80 population

Mark Fuerst Read Article
Published: 11/14/12

doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor-patient consulation
Credit: NIH

Though most studies of older patients with diffuse large B-cell lymphoma (DLBCL) have focused on individuals between 60 and 80 years of age, there are safe ways to treat patients who are even older, according to an expert. Andre Goy, MD, of the John Theurer Cancer Center in Hackensack, New Jersey, provided guidance for treating DLBCL patients who are older than 80 years of age during a presentation at Lymphoma & Myeloma 2012, which recently took place in New York, New York.  [Read Article]

GEP aids development of antitumor agents for DLBCL

Mark Fuerst Read Article
Published: 11/09/12

DNA_microarray_Credit_Guillaume_Paumier_230.jpg
DNA microarray
Credit: Guillaume Paumier

Gene expression profiling (GEP) using DNA microarrays is a major technological advance that has significantly increased our knowledge of non-Hodgkin lymphomas (NHLs), according to a speaker at Lymphoma & Myeloma 2012. And this knowledge is now being applied in the clinic to treat aggressive NHLs, such as diffuse large B-cell lymphoma (DLBCL), said Myron Czuczman, MD, of the Roswell Park Cancer Institute, at the recent meeting. He noted that GEP can be used to . . . [Read Article]

Immunomodulators ‘battle the Klingons’ in CLL

Erilyn Riley Read Article
Published: 11/07/12

Chanan-Khan_Asher_MD_240.jpg
Asher Chanan-Khan, MD

Calling CLL cells “real-life Klingons,” an expert described how the cells take center stage in the microenvironment, effectively remaining unchecked and growing right in front of the immune system. Asher Chanan-Khan, MD, of the Mayo Clinic in Rochester, Minnesota, made this comparison during a presentation at the recent meeting Lymphoma & Myeloma 2012. Dr Chanan-Khan also discussed the role of immunomodulating agents, particularly lenalidomide, in battling CLL. [Read Article]

Choosing the right mAB to treat CLL

Erilyn Riley Read Article
Published: 11/06/12

monoclonal_antibodies_Credit_Credit_Linda_Bartlett_230.jpg
Monoclonal antibodies
Credit: Linda Bartlett

About 11 newer monoclonal antibodies (mAbs) are currently in development for chronic lymphocytic leukemia (CLL). As these agents enter the market, choosing the best antibody therapy to treat CLL will become more difficult. To provide some guidance, Myron Czuczman, MD, of the Roswell Park Cancer Institute, reviewed data on these mAbs during his talk at Lymphoma & Myeloma 2012. Dr Czuczman first focused on a few next-generation anti-CD20 mAbs—ofatumumab, ublituximab . . . [Read Article]

Pros and cons of ‘continuous’ therapy for MM patients

Erilyn Riley Read Article
Published: 11/05/12

Giralt_Sergio_MD_240.jpg
Sergio Giralt, MD

The concept of maintenance therapy in multiple myeloma is not a new idea—it’s been around since the 1970s. Yet some experts maintain a healthy skepticism about whether maintenance therapy should be the standard of care in myeloma. Sergio Giralt, MD, of the Memorial Sloan-Kettering Cancer Center in New York, provided some perspective on the issue of maintenance therapy at Lymphoma & Myeloma 2012, held October 25–27. Stating that the appropriate . . . [Read Article]

Not all p53 abnormalities in CLL are created equal

Erilyn Riley Read Article
Published: 11/02/12

Lamanna_Nicole_MD_240.jpg
Nicole Lamanna, MD

The hierarchy of FISH defects in chronic lymphocytic leukemia (CLL) indicates that the 17p deletion ranks among the worst, having the poorest prognostic features. Yet de novo 17p deletion is not that common in CLL, occurring in only 7% of patients at diagnosis. The frequency of 17p and p53 abnormalities, however, increases with relapse. “Clearly, these are 2 different groups, and we need to think about them differently when we think about 17p patients,” said Nicole Lamanna, MD, of Memorial Sloan-Kettering . . .  [Read Article]

Time for a new definition of myeloma?

Erilyn Riley Read Article
Published: 11/01/12

Rajkumar_S Vincent_MD_240_v2.jpg
S. Vincent Rajkumar, MD

Patients with smoldering multiple myeloma (SMM) should be managed differently than patients with monoclonal gammopathy of unknown significance (MGUS), according to a speaker at Lymphoma & Myeloma 2012. S. Vincent Rajkumar, MD, of the Mayo Clinic in Rochester, Minnesota, noted that follow-up of MGUS patients is inadequate, with 16% percent of those who progress being missed on routine follow-up. On the other hand, about half of SMM patients remain progression-free after . . . [Read Article]

Less may be more in myeloma induction therapy

Erilyn Riley Read Article
Published: 10/31/12

Mikhael_Joseph_MD_240_v2.jpg
Joseph Mikhael, MD

Few myeloma patients warrant induction therapy with multiple novel agents, or at least so contends Joseph Mikhael, MD, of the Mayo Clinic in Rochester, Minnesota. His position is in direct opposition to an approach published in Blood in 2009 that recommends using all available drugs of known effectiveness during initial therapy. “You don’t want to bombard patients with everything all at once,” Dr Mikhael said. He provided evidence for his strategy, which . . . [Read Article]

Carfilzomib offers hope for MM patients with few options

Erilyn Riley Read Article
Published: 10/30/12

Siegel_David_MD_240.jpg
David Siegel, MD

An analysis of multiple myeloma patients from the pivotal trial of carfilzomib suggests the agent can be effective even in patients who are refractory to all 5 classes of standard therapy. “Refractoriness to IMiDs [immune modulators] did not seem to impact response to carfilzomib,” said David Siegel, MD, of Hackensack University Medical Center in New Jersey. Dr Siegel reported the exploratory subgroup analysis, selected as the best myeloma abstract, at . . . [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}